论文部分内容阅读
目的:探讨非小细胞肺癌(non-small cell lung cancer,NSCLC)组织中表皮生长因子受体(epidermal growth factor receptor,EGFR)及其磷酸化水平与患者临床生物学特征、临床治疗疗效间的关系。方法 :收集NSCLC患者75例,采用免疫组化检测其肿瘤组织中EGFR和磷酸化EGFR(p-EGFR)的表达水平,分析其与肺癌生物学特征及疗效间的关系。结果:本研究NSCLC患者的肿瘤组织中EGFR表达阳性率达78.67%,p-EGFR阳性率为56.00%,均明显高于癌旁肺组织;EGFR表达水平与肿瘤细胞的分化程度有关,而p-EGFR表达水平与肿瘤细胞的分化程度、淋巴结转移及临床分期均密切相关,低分化肿瘤细胞、发生肿瘤转移者的肿瘤组织、晚期肿瘤组织中的p-EGFR表达水平均明显升高。同时,p-EGFR水平与NSCLC患者临床治疗的有效率密切相关,p-EGFR表达阴性的患者其治疗有效率明显高于阳性者。结论:EGFR的磷酸化形式在判断NSCLC疾病进展及临床疗效时可能更有实用意义,在评估NSCLC患者的临床疗效及预后判断中具有一定价值。
OBJECTIVE: To investigate the relationship between epidermal growth factor receptor (EGFR) and its phosphorylation levels in patients with non-small cell lung cancer (NSCLC) and their clinical characteristics and clinical efficacy . Methods: Seventy-five NSCLC patients were collected. The expression of EGFR and phosphorylated EGFR (p-EGFR) was detected by immunohistochemistry. The relationship between the expression of EGFR and phosphorylated EGFR (p-EGFR) was analyzed. Results: The positive rate of EGFR expression in NSCLC patients was 78.67% and the positive rate of p-EGFR was 56.00% in NSCLC patients, which were significantly higher than that in para-cancerous lung tissues. The expression of EGFR was related to the differentiation of tumor cells, The expression of EGFR was closely related to the differentiation of tumor cells, lymph node metastasis and clinical stage. The expression of p-EGFR in poorly differentiated tumor cells, tumor tissues with metastasis and advanced stage tumor tissues were significantly increased. Meanwhile, the level of p-EGFR is closely related to the clinical efficacy of NSCLC patients. The effective rate of p-EGFR expression in patients with negative p-EGFR is significantly higher than that in patients with positive p-EGFR. CONCLUSION: The phosphorylated form of EGFR may be more useful in judging the progression of NSCLC disease and its clinical curative effect. It is of great value in assessing the clinical curative effect and prognosis of NSCLC patients.